Figure 5. Complement-dependent LTB4 release and binding of LTB4 to OmCI.
Left panels: Pig and human whole blood was preincubated with 0.64 μM OmCI or albumin and human whole blood was also preincubated with the human specific C inhibitors compstatin (25 μM) and eculizumab (0.67 μM), thereafter incubated with 106 E. coli/ml for 120 minutes at 37 °C. Data are presented as mean ± SEM (n = 3 for pig and n = 7 for human). Statistics were performed on the effect of the C inhibitors versus the effect of E. coli only, *p < 0.05.
Right panels: LTB4-enriched plasma was generated by incubating pig and human whole blood with 106 E. coli/ml for 120 minutes at 37 °C. Thereafter OmCI was added to the activated plasma and incubated for 15 minutes at 37 °C. A control peptide or eculizumab were used as controls for pig and human respectively. Samples were then analysed for LTB4. Data are normalized to LTB4 in E. coli activated plasma (defined as 100%). Data are presented as mean ± SEM for human (n = 4), and as mean for pig (n = 2).